Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1695 - Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: results from the AGMT_MBC-Registry

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Breast Cancer

Presenters

Simon Peter Gampenrieder

Citation

Annals of Oncology (2019) 30 (suppl_5): v104-v142. 10.1093/annonc/mdz242

Authors

S.P.P. Gampenrieder1, G. Rinnerthaler1, A. Petzer2, C. Tinchon3, D. Fuchs4, M. Balic5, S. Heibl6, H. Rumpold7, D. Egle8, A.F. Zabernigg9, C.F. Singer10, J. Andel11, M. Hubalek12, M. Knauer13, R. Greil1

Author affiliations

  • 1 Department Of Internal Medicine Iii With Haematology, Medical Oncology, Haemostaseology, Infectiology And Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory For Immunological And Molecular Cancer Research (scri-limcr), Paracelsus Medical University, 5020 - Salzburg/AT
  • 2 Internal Medicine I For Hematology With Stem Cell Transplantation, Hemostaseology And Medical Oncology, Ordensklinikum Linz Barmherzige Schwestern - Elisabethinen, Linz/AT
  • 3 Internal Medicine - Department For Haemato-oncology, LKH Hochsteiermark, Leoben/AT
  • 4 Department Of Hematology And Internal Oncology, Kepler University Hospital, Johannes Kepler University Linz, Linz/AT
  • 5 Division Of Oncology, Department For Internal Medicine, Medical University Graz, Graz/AT
  • 6 Department Of Internal Medicine Iv, Klinikum Wels-Grieskirchen GmbH, Wels/AT
  • 7 Department Of Internal Medicine Iii With Haematology, Medical Oncology, Haemostaseology, Infectiology And Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory For Immunological And Molecular Cancer Research (scri-limcr), Academic Teaching Hospital Feldkirch, Feldkirch/AT
  • 8 Department Of Gynaecology, Medical University Innsbruck, Innsbruck/AT
  • 9 Department Of Internal Medicine Iii With Haematology, Medical Oncology, Haemostaseology, Infectiology And Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory For Immunological And Molecular Cancer Research (scri-limcr), County Hospital Kufstein, Kufstein/AT
  • 10 Department Of Obstetrics And Gynecology And Comprehensive Cancer Center, Medical University of Vienna, Vienna/AT
  • 11 Department Of Internal Medicine Iii With Haematology, Medical Oncology, Haemostaseology, Infectiology And Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory For Immunological And Molecular Cancer Research (scri-limcr), Landeskrankenhaus Steyr, Steyr/AT
  • 12 Department Of Gynecology, Breast Health Center Schwaz, Country Hospital Schwaz, Schwaz/AT
  • 13 /, Breast Center Eastern Switzerland, St. Gallen/CH

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1695

Background

Both pertuzumab and T-DM1 improved overall survival (OS) of HER2+ metastatic breast cancer (MBC) in clinical trials. Little is known about their activity outside of clinical trials and when administered sequentially or after (neo)adjuvant pretreatment. Here we present real-word data from the MBC-Registry of the Austrian Study Group of Medical Tumor Therapy (AGMT).

Methods

The AGMT-MBC-Registry is a multicenter nationwide ongoing retrospective and prospective registry for MBC patients in Austria. Unadjusted, univariate survival probabilities of PFS and OS were calculated by the Kaplan-Meier method and compared by the log-rank test, multivariate hazard ratios (HR) were estimated by Cox regression models. In this analysis patients with known HER2 status and available survival data who received at least one palliative treatment line were included.

Results

As of 31/01/2019, 1262 patients were included in the AGMT-MBC-Registry. Out of 1090 evaluable patients, 256 (23.5%) were HER2+. Compared to patients with HER2- disease, HER2 positivity was significantly associated with longer OS (median OS 42.7 vs. 33.6 months; HR 0.80; 95%CI 0.67-0.96; P = 0.017). Patients treated with pertuzumab (106/256=41.4%) or T-DM1 (49/256=19.1%) had a significantly longer OS than patients who were not treated with these agents, respectively (HR 0.35; 95%CI 0.24-0.52; P < 0.001 and HR 0.48; 95%CI 0.31-0.75; P = 0.001). Furthermore, pertuzumab treatment was significantly associated with longer OS in multivariate analysis (P < 0.001). Median PFS of pertuzumab containing treatments was significantly longer when administered in first-line compared to later lines (23.7 vs. 6.3 months; HR 0.35; 95%CI 0.21-0.58; P < 0.001). In T-DM1 treated patients, median PFS of T-DM1 was longer when given in first- or second-line compared to later lines (11.0 vs. 8.4 months) and in pertuzumab naïve patients (11.0 vs. 7.6 months). However, these differences were not statistically significant.

Conclusions

Prognosis of HER2+ MBC has significantly improved by the implementation of pertuzumab and T-DM1 in this real-world population.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Richard Greil.

Funding

Roche, Pfizer.

Disclosure

S.P.P. Gampenrieder: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Speaker Bureau / Expert testimony: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Eli Lilly; Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: Shire; Travel / Accommodation / Expenses: Bayer; Travel / Accommodation / Expenses: Celgene; Travel / Accommodation / Expenses: Daiichy Sankyo. G. Rinnerthaler: Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Celgene; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Lilly; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Amgen; Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: BMS. A. Petzer: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Lilly; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche. D. Fuchs: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: Tesa. M. Balic: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Amgen; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pierre Fabre; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Samsung; Speaker Bureau / Expert testimony, Research grant / Funding (self): Celgene; Travel / Accommodation / Expenses: BMS; Travel / Accommodation / Expenses: Boehringer Ingelheim. D. Egle: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Lilly; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. A.F. Zabernigg: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer. C.F. Singer: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Novartis; Honoraria (self), Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Honoraria (self), Research grant / Funding (self), Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Pfizer. M. Hubalek: Honoraria (self): Pfizer; Honoraria (institution): AstraZeneca; Advisory / Consultancy: Novartis; Speaker Bureau / Expert testimony: Lilly; Research grant / Funding (self): Amgen; Travel / Accommodation / Expenses: Roche. R. Greil: Honoraria (self), Advisory / Consultancy: Daiichy Sankyo; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Honoraria (self), Research grant / Funding (self): Tarkeda; Honoraria (self), Research grant / Funding (self): Celgene; Honoraria (institution), Research grant / Funding (self): Novartis; Honoraria (self): BMS; Honoraria (self): Amgen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.